The study compared CARVYKTI's efficacy and safety against standard-of-care regimens in patients with multiple myeloma.

We recently compiled a list of the 12 NASDAQ Stocks with Biggest Upside Potential According to Analysts. In this article, we ...

We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, we are going to take a look ...

Johnson & Johnson (JNJ) said that Health Canada has issued a Notice of Compliance for CARVYKTI (ciltacabtagene autoleucel) for the ...

ABBV stock has seen strong gains of 85% from levels of $90 in early January 2021 to around $165 now, vs. an increase of about ...

Santhosh K. Sadashiv, MD, discusses the role of chimeric antigen receptor T-cell therapy in patients with multiple myeloma.

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Legend Biotech (LEGN – Research Report) and keeping the price ...

Net Trade Sales of CARVYKTI: Approximately $286 million, an 87.6% increase year-over-year and a 53.2% increase ...

智通财经APP讯，金斯瑞生物科技(01548)公布传奇生物2024年第三季度业绩， CARVYKTI (西达基奥仑赛;cilta-cel)净贸易销售额约为2.86亿美元，营收同比增长87.6%，环比增长 53.2%。 合作收入为1.428亿美元 ...

作为长期战略的一部分，传奇生物在进一步扩大产能的同时，也在积极推进研发项目，以巩固其在细胞治疗创新领域的领导地位。该公司计划在美国宾夕法尼亚州费城新建全球领先的细胞疗法研发设施，预计该设施将于2025年第三季度完工。外界认为，这将进一步扩展传奇生物在 ...

Authorization is based on results from the Phase 3 CARTITUDE-4 (MMY3002) study, which showed treatment with CARVYKTI® reduced the risk of disease progression or death by 74 per cent compared to ...

周三，Cantor Fitzgerald将Legend Biotech Corp. (NASDAQ:LEGN)的目标价从之前的82.00美元上调至83.00美元，同时维持对该股的增持评级。该公司分析师强调，最近美国血液学会（ASH）会议上anito-cel摘要数据引发的激烈讨论，已经盖过了Legend Biotech第三季度财报电话会议的关注度。 面对市场对竞争对手数据的反应，Legend Bio ...